Absci Advances ABS-101, a Promising Anti-TL1A Antibody Developed via Generative AI, Toward IND Filing

Absci Corporation, represented by its stock ticker ABSI, is progressing with the preclinical development of its innovative therapeutic, ABS-101. This candidate, born from a cutting-edge generative artificial intelligence platform, has been initiated into IND-enabling studies with the goal to establish a potential best-in-class treatment modality against TL1A, a target implicated in various inflammatory and autoimmune diseases.

Initiation of IND-Enabling Studies

ABS-101 stands at the forefront of Absci’s pipeline, showcasing the company's dedication to harnessing generative AI for the creation and optimization of novel biologics. The commencement of IND-enabling studies marks a pivotal step toward bringing ABS-101 closer to clinical evaluation. With these studies, Absci aims to gather adequate data to support an Investigational New Drug (IND) application to regulatory authorities.

Pathway to Clinical Trials

Subsequent to the anticipated filing of an IND, projected for the first quarter of 2025, Absci plans to rapidly transition ABS-101 to Phase 1 clinical trials. The swift movement from the regulatory filing to patient trials underscores the company's commitment to addressing unmet clinical needs through its AI-driven drug discovery and development platform. Investors and industry observers alike are attentively watching ABSI as it embarks on this critical phase of ABS-101's journey.

IND, pharmaceutical, AI